BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Cipla
AstraZeneca
Moodys
Federal Trade Commission
Deloitte
US Army
McKesson
Colorcon

Generated: January 19, 2018

DrugPatentWatch Database Preview

Sanofi Aventis Us Company Profile

« Back to Dashboard

Summary for Sanofi Aventis Us
International Patents:1042
US Patents:57
Tradenames:113
Ingredients:93
NDAs:136

Drugs and US Patents for Sanofi Aventis Us

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us LANTUS SOLOSTAR insulin glargine recombinant INJECTABLE;INJECTION 021081-002 Apr 27, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sanofi Aventis Us CYANOCOBALAMIN cyanocobalamin INJECTABLE;INJECTION 080564-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us DANOCRINE danazol CAPSULE;ORAL 017557-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us METAHYDRIN trichlormethiazide TABLET;ORAL 012594-002 Jun 16, 1988 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us TALACEN acetaminophen; pentazocine hydrochloride TABLET;ORAL 018458-001 Sep 23, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us PHISOHEX hexachlorophene EMULSION;TOPICAL 008402-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us PRESAMINE imipramine hydrochloride TABLET;ORAL 011836-007 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us SKELID tiludronate disodium TABLET;ORAL 020707-001 Mar 7, 1997 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us HYGROTON chlorthalidone TABLET;ORAL 012283-003 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Sanofi Aventis Us

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-001 Mar 29, 1993 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us PENETREX enoxacin TABLET;ORAL 019616-005 Dec 31, 1991 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us TORNALATE bitolterol mesylate SOLUTION;INHALATION 019548-001 Feb 19, 1992 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us ALLEGRA HIVES fexofenadine hydrochloride TABLET;ORAL 020872-009 Jan 24, 2011 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER milrinone lactate INJECTABLE;INJECTION 020343-002 Aug 9, 1994 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us PRIMACOR milrinone lactate INJECTABLE;INJECTION 019436-001 Dec 31, 1987 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us AVALIDE hydrochlorothiazide; irbesartan TABLET;ORAL 020758-002 Sep 30, 1997 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride TABLET;ORAL 020872-005 Jan 24, 2011 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us NASACORT ALLERGY 24 HOUR triamcinolone acetonide SPRAY, METERED;NASAL 020468-002 Oct 11, 2013 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021492-001 Aug 9, 2002 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SANOFI AVENTIS US drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Transdermal System 7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs ➤ Subscribe 5/30/2014
➤ Subscribe Tablets 400 mg ➤ Subscribe 7/1/2013
➤ Subscribe Injection 5 mg/mL, 40 mL vial ➤ Subscribe 3/23/2011
➤ Subscribe Oral Suspension 30 mg/5 mL ➤ Subscribe 1/25/2010
➤ Subscribe Injection 40 mg/mL, 0.5 mL and 2 mL vials ➤ Subscribe 6/30/2009
➤ Subscribe Tablets 300 mg ➤ Subscribe 3/4/2009
➤ Subscribe Injection 200 mg/40 mL ➤ Subscribe 7/16/2007
➤ Subscribe Injection 5 mg/mL, 10 mL and 20 mL vials ➤ Subscribe 2/9/2007
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 2/9/2007
➤ Subscribe Injection 100 mg/mL, 3 mL vials ➤ Subscribe 12/7/2006
➤ Subscribe Tablets 300 mg/25 mg ➤ Subscribe 6/6/2006
➤ Subscribe Extended-release Tablets 6.25 mg ➤ Subscribe 2/24/2006
➤ Subscribe Extended-release Tablets 12.5 mg ➤ Subscribe 1/19/2006
➤ Subscribe Tablets 150 mg/12.5 mg and 300 mg/12.5 mg ➤ Subscribe 11/10/2004
➤ Subscribe Tablets 75 mg, 150 mg and 300 mg ➤ Subscribe 5/25/2004
Premature patent expirations for SANOFI AVENTIS US

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for Sanofi Aventis Us

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,888,750 Pen-type injector ➤ Subscribe
6,218,553 Process for the preparation of taxane derivatives and .beta.-lactam intermediates therefor ➤ Subscribe
6,375,984 Aqueous-based pharmaceutical composition ➤ Subscribe
7,205,276 Zinc-free and low-zinc insulin preparations having improved stability ➤ Subscribe
6,100,404 Erythromycin compounds ➤ Subscribe
7,205,277 Zinc-free and low-zinc insulin preparations having improved stability ➤ Subscribe
6,372,780 Methods of treating cell lines expressing multidrug resistance P-glycoprotein ➤ Subscribe
6,399,632 Method of providing an antihistaminic effect in a hepatically impaired patient ➤ Subscribe
7,122,206 Aqueous-based pharmaceutical composition ➤ Subscribe
7,553,299 Drive mechanisms suitable for use in drug delivery devices ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Sanofi Aventis Us Drugs

Supplementary Protection Certificates for Sanofi Aventis Us Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
14/004 Ireland ➤ Subscribe PRODUCT NAME: TERIFLUNOMIDE, ITS STEREOISOMER AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/838/001-005 20130826
C008/2010 Ireland ➤ Subscribe SPC008/2010: 20101015, EXPIRES: 20230616
C/GB00/021 United Kingdom ➤ Subscribe PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
C/GB05/024 United Kingdom ➤ Subscribe PRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/04/285/001 - 020 20040929
C0044 Belgium ➤ Subscribe PRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615
60002 Netherlands ➤ Subscribe PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127
C0006 Belgium ➤ Subscribe PRODUCT NAME: TILUDRONATE DISODIQUE EXPRIME EN ACIDE TILUDRONIQUE; NAT. REGISTRATION NO/DATE: 201 IS 106 F 3 19950907; FIRST REGISTRATION: LI 53014 19950220
/2004 Austria ➤ Subscribe PRODUCT NAME: INSULIN-DETEMIR UND PHARMAZEUTISCH ANNEHMBARE ZN-SALZE DAVON; NAT. REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601; FIRST REGISTRATION: LI 56370 56371 56372 20031110
2017 00013 Denmark ➤ Subscribe PRODUCT NAME: KOMBINATION AF INSULIN DEGLUDEC OG LIRAGLUTID; NAT. REG. NO/DATE: EU/1/14/947 20140922; FIRST REG. NO/DATE: CH 65041 20140912
90064-1 Sweden ➤ Subscribe PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Express Scripts
Baxter
Cipla
Federal Trade Commission
Boehringer Ingelheim
Farmers Insurance
UBS
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot